Early clinical stage therapeutics company developing BNAD101, a patent-pending oral composition of NAD+ clinically proven to increase intracellular NAD+. BNAD101 is a potential high-value medicine to treat challenging and costly neurological disorders. In 2022, the Company completed its double-blind, placebo-controlled proof of concept study at the Institute of Systems Biology. The study of 60 healthy adults demonstrated BNAD101 had a 52% increase in intracellular NAD levels against placebo within just 5 days, effectively validating the potential of BNAD101 in treating not only chronic neurological conditions but conditions were swift response is critical. Bryleos: More Life While Living
Location: United States, Tennessee, Johnson City
Employees: 1-10
Total raised: $5M
Founded date: 2021
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.06.2023 | Seed | $5M | - |
Mentions in press and media 2
| Date | Title | Description | Source |
| 13.06.2023 | Bryleos Raises $5M in Seed Funding | Bryleos (fka BioNADrx), a Nashville, TN-based clinical stage therapeutics company, raised $5M in See... | finsmes.co... |
| - | Bryleos | “Novel oral composition of NAD+ clinically proven to increase intracellular NAD, A potential high-va... | fastfounde... |